British drugmaker GSK announced that its cancer drug Jemperli has achieved the primary goal of overall survival in patients with primary advanced or recurrent endometrial cancer in a late-stage trial.
- British drugmaker GSK said on Monday its cancer drug Jemperli met the primary goal of overall survival in patients with primary advanced or recurrent endometrial cancer in a late-stage trial .
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:
GSK Cancer Drug Jemperli Late-Stage Trial Overall Survival Primary Advanced Endometrial Cancer Recurrent Endometrial Cancer